Loading
A phase 2 trial of Rituximab, Filgrastim and Granisetron in Leukaemia and Mantle cell lymphoma, run by Stanford University, completed.
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD is a phase 2 interventional study registered as NCT00186628 by Stanford University, with 36 participants recorded, started 2005-06 and reaching its primary completion in 2010-11. Interventions recorded: Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone. Conditions recorded: Leukemia, Mast-Cell, Mantle-cell Lymphoma.
Linked to the drug Granisetron because the registry names it among its interventions and Leukaemia and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
36 enrolled.
95% CI 6 to 34; Figures from the ClinicalTrials.gov results section (first posted 2017-11-28), not from a publication
Source95% CI 57 to 94; Figures from the ClinicalTrials.gov results section (first posted 2017-11-28), not from a publication · 95% CI 48 to 99
SourceShares Rituximab, Mantle cell lymphoma and the tag pipeline.
Shares Rituximab, Leukaemia (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF), Leukaemia (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF), Rituximab and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.